Can the duration of tuberculosis treatment be shortened with higher dosages of rifampicin?

Frontiers in Microbiology

Volumn 6, Issue OCT, 2015, Pages

  Dutta, Noton K ^a   Karakousis, Petros C ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Animal models; Clinical trial; Mycobacterium tuberculosis; Persistence; Reactivation; Rifampicin; Treatment improvement

Indexed keywords

BACTERIAL DNA; BEDAQUILINE; EFAVIRENZ; ETHAMBUTOL; ETHYLENEDIAMINE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE;

BACTERICIDAL ACTIVITY; CLINICAL TRIAL (TOPIC); DRUG BIOAVAILABILITY; DRUG PROTEIN BINDING; NONHUMAN; NOTE; POINT MUTATION; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOUS ARTHRITIS;

EID: 84946846008     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2015.01117     Document Type: Note

References (36)

1. (1972). Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1, 1079-1085.
2. Billington, O. J., McHugh, T. D., and Gillespie, S. H. (1999). Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 43, 1866-1869.
3. Bodmer, T., Zürcher, G., Imboden, P., and Telenti, A. (1995). Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. J. Antimicrob. Chemother. 35, 345-348. doi: 10.1093/jac/35.2.345
4. Boeree, M. J., Diacon, A. H., Dawson, R., Narunsky, K., du Bois, J., Venter, A., et al. (2015). A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 191, 1058-1065. doi: 10.1164/rccm.201407-1264OC
5. Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., et al. (2001). Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell 104, 901-912. doi: 10.1016/S0092-8674(01)00286-0
6. de Steenwinkel, J. E., Aarnoutse, R. E., de Knegt, G. J., ten Kate, M. T., Teulen, M., Verbrugh, H. A., et al. (2013). Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. Am. J. Respir. Crit. Care Med. 187, 1127-1134. doi: 10.1164/rccm.201207-1210OC
7. Diacon, A. H., Patientia, R. F., Venter, A., van Helden, P. D., Smith, P. J., McIlleron, H., et al. (2007). Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob. Agents Chemother. 51, 2994-2996. doi: 10.1128/AAC.01474-06
8. Dutta, N. K., Alsultan, A., Peloquin, C. A., and Karakousis, P. C. (2013). Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs. Antimicrob. Agents Chemother. 57, 1535-1537. doi: 10.1128/AAC.01933-12
9. Dutta, N. K., Illei, P. B., Peloquin, C. A., Pinn, M. L., Mdluli, K. E., Nuermberger, E. L., et al. (2012). Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob. Agents Chemother. 56, 3726-3731. doi: 10.1128/AAC.00500-12
10. Gillespie, S. H., Crook, A. M., McHugh, T. D., Mendel, C. M., Meredith, S. K., Murray, S. R., et al. (2014). Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N. Engl. J. Med. 371, 1577-1587. doi: 10.1056/NEJMoa1407426
11. Goutelle, S., Bourguignon, L., Maire, P. H., van Guilder, M., Conte, J. E. Jr., and Jelliffe, R. W. (2009). Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob. Agents Chemother. 53, 2974-2981. doi: 10.1128/AAC.01520-08
12. Gumbo, T., Louie, A., Deziel, M. R., Liu, W., Parsons, L. M., Salfinger, M., et al. (2007). Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 51, 3781-3788. doi: 10.1128/AAC.01533-06
13. Hartmann, G., Honikel, K. O., Knüsel, F., and Nüesch, J. (1967). The specific inhibition of the DNA-directed RNA synthesis by rifamycin. Biochim. Biophys. Acta 145, 843-844. doi: 10.1016/0005-2787(67)90147-5
14. Hu, Y., Liu, A., Ortega-Muro, F., Alameda-Martin, L., Mitchison, D., and Coates, A. (2015). High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo. Front. Microbiol. 6:641. doi: 10.3389/fmicb.2015.00641
15. Jayaram, R., Gaonkar, S., Kaur, P., Suresh, B. L., Mahesh, B. N., Jayashree, R., et al. (2003). Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47, 2118-2124. doi: 10.1128/AAC.47.7.2118-2124.2003
16. Jin, D. J., and Gross, C. A. (1991). RpoB8, a rifampicin-resistant termination-proficient RNA polymerase, has an increased Km for purine nucleotides during transcription elongation. J. Biol. Chem. 266, 14478-14485.
17. Lenaerts, A., Barry, C. E. III, and Dartois, V. (2015). Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol. Rev. 264, 288-307. doi: 10.1111/imr.12252
18. Li, G., Zhang, J., Guo, Q., Wei, J., Jiang, Y., Zhao, X., et al. (2015). Study of efflux pump gene expression in rifampicin-monoresistant Mycobacterium tuberculosis clinical isolates. J. Antibiot. 68, 431-435. doi: 10.1038/ja.2015.9
19. Louw, G. E., Warren, R. M., Gey van Pittius, N. C., Leon, R., Jimenez, A., Hernandez-Pando, R., et al. (2011). Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am. J. Respir. Crit. Care Med. 184, 269-276. doi: 10.1164/rccm.201011-1924OC
20. Lyons, M. A., Reisfeld, B., Yang, R. S., and Lenaerts, A. J. (2013). A physiologically based pharmacokinetic model of rifampin in mice. Antimicrob. Agents Chemother. 57, 1763-1771. doi: 10.1128/AAC.01567-12
21. Mariam, D. H., Mengistu, Y., Hoffner, S. E., and Andersson, D. I. (2004). Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48, 1289-1294. doi: 10.1128/AAC.48.4.1289-1294.2004
22. Moghazeh, S. L., Pan, X., Arain, T., Stover, C. K., Musser, J. M., and Kreiswirth, B. N. (1996). Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob. Agents Chemother. 40, 2655-2657.
23. Pasipanodya, J. G., McIlleron, H., Burger, A., Wash, P. A., Smith, P., and Gumbo, T. (2013). Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J. Infect. Dis. 208, 1464-1473. doi: 10.1093/infdis/jit352
24. Peloquin, C. A., Jaresko, G. S., Yong, C. L., Keung, A. C., Bulpitt, A. E., and Jelliffe, R. W. (1997). Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob. Agents Chemother. 41, 2670-2679.
25. Piddock, L. J., Williams, K. J., and Ricci, V. (2000). Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis. J. Antimicrob. Chemother. 45, 159-165. doi: 10.1093/jac/45.2.159
26. Rosenthal, I. M., Tasneen, R., Peloquin, C. A., Zhang, M., Almeida, D., Mdluli, K. E., et al. (2012). Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob. Agents Chemother. 56, 4331-4340. doi: 10.1128/AAC.00912-12
27. Savic, R. M., Lu, Y., Bliven-Sizemore, E., Weiner, M., Nuermberger, E., Burman, W., et al. (2014). Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob. Agents Chemother. 58, 3035-3042. doi: 10.1128/AAC.01918-13
28. Shah, N. S., Wright, A., Bai, G. H., Barrera, L., Boulahbal, F., Martín-Casabona, N., et al. (2007). Worldwide emergence of extensively drug-resistant tuberculosis. Emerging Infect. Dis. 13, 380-387. doi: 10.3201/eid1303.061400
29. Steingart, K. R., Jotblad, S., Robsky, K., Deck, D., Hopewell, P. C., Huang, D., et al. (2011). Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int. J. Tuberc. Lung Dis. 15, 305-316.
30. Svensson, E. M., Murray, S., Karlsson, M. O., and Dooley, K. E. (2015). Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J. Antimicrob. Chemother. 70, 1106-1114. doi: 10.1093/jac/dku504
31. van Ingen, J., Aarnoutse, R. E., Donald, P. R., Diacon, A. H., Dawson, R., Plemper van Balen, G., et al. (2011). Why do we use 600 mg of Rifampicin in tuberculosis treatment? Clin. Infect. Dis. 52, e194-e199. doi: 10.1093/cid/cir184
32. Wade, M. M., and Zhang, Y. (2004). Mechanisms of drug resistance in Mycobacterium tuberculosis. Front. Biosci. 9, 975-994. doi: 10.2741/1289
33. Wilkins, J. J., Savic, R. M., Karlsson, M. O., Langdon, G., McIlleron, H., Pillai, G., et al. (2008). Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob. Agents Chemother. 52, 2138-2148. doi: 10.1128/AAC.00461-07
34. Williams, D. L., Spring, L., Collins, L., Miller, L. P., Heifets, L. B., Gangadharam, P. R., et al. (1998). Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42, 1853-1857.
35. Zhang, Z., Dai, F., Luo, F., Zhong, M., Huang, Z., Hou, T., et al. (2014). Could high-concentration rifampicin kill rifampicin-resistant M. tuberculosis ? Rifampicin MIC test in rifampicin-resistant isolates from patients with osteoarticular tuberculosis. J. Orthop. Surg. Res. 9, 124. doi: 10.1186/s13018-014-0124-1
36. Ziglam, H. M., Baldwin, D. R., Daniels, I., Andrew, J. M., and Finch, R. G. (2002). Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 50, 1011-1015. doi: 10.1093/jac/dkf214